Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prochlorperazine

FDA-approved product (suppository, rectal), marketed as Compazine, Compro, Prochlorperazine and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Prochlorperazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Nausea and vomiting
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
FDA pharmacologic class
Phenothiazine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis74.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prochlorperazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prochlorperazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

    NCT06904287 · start 2025-12-16

    Registered record
    Registry ID
    NCT06904287
    Conditions
    Migraine
    Interventions
    Magnesium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-16
    Completion
    2027-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionMagnesium; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

    NCT06450899 · start 2024-08-05

    Registered record
    Registry ID
    NCT06450899
    Conditions
    Acute Mountain Sickness
    Interventions
    Prochlorperazine Maleate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-08-05
    Completion
    2024-08-28
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Mountain Sickness
    InterventionProchlorperazine Maleate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

    NCT05856773 · start 2024-03-21

    Registered record
    Registry ID
    NCT05856773
    Conditions
    Breast Cancer
    Interventions
    Proton Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-03-21
    Completion
    2041-02
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionProton Therapy
    PhasePhase 3
    Registry statusRecruiting

  • Intranasal Ketorolac Trial

    NCT06083571 · start 2024-01-01

    Registered record
    Registry ID
    NCT06083571
    Conditions
    Headache, Migraine
    Interventions
    Ketorolac; Prochlorperazine; Diphenhydramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache, Migraine
    InterventionKetorolac; Prochlorperazine; Diphenhydramine
    PhasePhase 2
    Registry statusTerminated

  • Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

    NCT05013437 · start 2023-09

    Registered record
    Registry ID
    NCT05013437
    Conditions
    Multiple Myeloma
    Interventions
    Evomela; Next Generation Sequencing; Prochlorperazine; Acetaminophen; Diphenhydramine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2023-09
    Completion
    2024-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionEvomela; Next Generation Sequencing; Prochlorperazine; Acetaminophen +1 more
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Intravenous Fluids in Pediatric Migraine

    NCT06182098 · start 2023-06-27

    Registered record
    Registry ID
    NCT06182098
    Conditions
    Migraine; Migraine in Children
    Interventions
    1/2 maintenance fluids; Ketorolac; Diphenhydramine; Prochlorperazine; bolus
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-27
    Completion
    2025-06
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine in Children
    Intervention1/2 maintenance fluids; Ketorolac; Diphenhydramine; Prochlorperazine +1 more
    PhaseNot applicable
    Registry statusUnknown

  • 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

    NCT05317000 · start 2023-03-23

    Registered record
    Registry ID
    NCT05317000
    Conditions
    Squamous Cell Carcinoma of Head and Neck
    Interventions
    Combination 5-azacytidine and nivolumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-03-23
    Completion
    2028-11-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of Head and Neck
    InterventionCombination 5-azacytidine and nivolumab; Nivolumab
    PhasePhase 2
    Registry statusRecruiting

  • Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

    NCT05768919 · start 2023-03-03

    Registered record
    Registry ID
    NCT05768919
    Conditions
    Glioblastoma
    Interventions
    Treatment Period 1; Treatment Period 2; Treatment Period 3; Treatment Period 4a
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-03-03
    Completion
    2027-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionTreatment Period 1; Treatment Period 2; Treatment Period 3; Treatment Period 4a
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo.

    NCT05586763 · start 2022-02-01

    Registered record
    Registry ID
    NCT05586763
    Conditions
    Peripheral Vertigo
    Interventions
    Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-02-01
    Completion
    2024-12-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Vertigo
    InterventionMetoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

    NCT06310642 · start 2021-05-20

    Registered record
    Registry ID
    NCT06310642
    Conditions
    AMS; Acute Mountain Sickness
    Interventions
    Immediate descent from altitude.; Diphenhydramine; Prochlorperazine 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-20
    Completion
    2023-03-13
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAMS; Acute Mountain Sickness
    InterventionImmediate descent from altitude.; Diphenhydramine; Prochlorperazine 10 mg
    PhasePhase 4
    Registry statusCompleted

  • Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

    NCT04503668 · start 2020-12-28

    Registered record
    Registry ID
    NCT04503668
    Conditions
    Gynecologic Cancer
    Interventions
    Ondansetron; Dexamethasone; Neurokinin-1 Receptor Antagonist (NK1-RA); Olanzapine; Compazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-12-28
    Completion
    2024-03-11
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGynecologic Cancer
    InterventionOndansetron; Dexamethasone; Neurokinin-1 Receptor Antagonist (NK1-RA); Olanzapine +1 more
    PhasePhase 3
    Registry statusTerminated

  • Paracervical Injection for Headache in the Emergency Department

    NCT04109885 · start 2020-09-15

    Registered record
    Registry ID
    NCT04109885
    Conditions
    Headache Disorders, Primary; Pain Management; Emergency Department
    Interventions
    Paracervical injection; prochlorperazine and diphenhydramine.(Standard Treatment)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-09-15
    Completion
    2024-01-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache Disorders, Primary; Pain Management; Emergency Department
    InterventionParacervical injection; prochlorperazine and diphenhydramine.(Standard Treatment)
    PhasePhase 2
    Registry statusTerminated

  • SPG Blocks for Headaches

    NCT04255420 · start 2020-02-21

    Registered record
    Registry ID
    NCT04255420
    Conditions
    Headache
    Interventions
    SPG Block; Standard IV Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-02-21
    Completion
    2021-06-01
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache
    InterventionSPG Block; Standard IV Treatment
    PhasePhase 4
    Registry statusUnknown

  • Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

    NCT05967442 · start 2019-08-23

    Registered record
    Registry ID
    NCT05967442
    Conditions
    Migraine; Headache
    Interventions
    Magnesium Sulfate; Metoclopramide 10mg; Prochlorperazine (Compazine) Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-23
    Completion
    2023-04-06
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Headache
    InterventionMagnesium Sulfate; Metoclopramide 10mg; Prochlorperazine (Compazine) Injection
    PhasePhase 3
    Registry statusCompleted

  • SPG Block for Acute Pediatric Migraine

    NCT03984045 · start 2019-06-06

    Registered record
    Registry ID
    NCT03984045
    Conditions
    Migraine in Children; Sphenopalatine Neuralgia; Migraine in Adolescence
    Interventions
    Lidocaine topical; Prochlorperazine Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-06-06
    Completion
    2022-12-30
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine in Children; Sphenopalatine Neuralgia; Migraine in Adolescence
    InterventionLidocaine topical; Prochlorperazine Injection
    PhasePhase 3
    Registry statusUnknown